Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ:TRHC), a healthcare
technology company advancing the field of medication safety, today
announced its financial results for the third quarter ended
September 30, 2019.
“The third quarter for Tabula Rasa was filled with positive
developments with respect to sales and I believe that the
integration efforts with our recent acquisitions are beginning to
pay off. For example, during the quarter, we transitioned a
SinfoníaRx client in the managed Medicaid market to MedWise and
those services will launch in the fourth quarter. Further, we added
MedWise services to an existing Medicare Medication Therapy
Management (MTM) customer, which will begin in 2020. Within the
PrescribeWellness Patient Engagement Center, we embedded the
MedWise Risk Score for the pharmacies in which we launched our
Concierge Pharmacist pilot. These successes validate our strategy
to target SinfoníaRx and PrescribeWellness clients and
pharmacists,” said Calvin H. Knowlton, PhD, TRHC’s Chairman and
Chief Executive Officer.
“In addition, the investments we made integrating the MedWise
platform into EHRs are beginning to demonstrate value. In the
fourth quarter, we expect to launch the MedWise platform in Cerner
employee clinics, which is generally viewed as their test site for
future product enhancements. We also contracted with a Federally
Qualified Health Center, which will be leveraging our athenahealth
integration to manage their patients who have a high MedWise Risk
Score™.”
“We also continue to gain market share in PACE and have signed
our first for-profit PACE organization focused on rapid national
market expansion. We are thrilled about this partnership as this
for-profit PACE organization has outlined a very exciting growth
plan. Further, we have 15 new PACE locations under contract, which
we expect will open in 2020, three of which are locations from the
aforementioned for-profit PACE agreement.”
Dr. Knowlton continued, “While we have many things to celebrate,
we did receive news that a large adherence contract we previously
announced was abruptly cancelled during the third quarter. Our
client reorganized management responsible for their adherence
programs as a result of a recent merger and is reevaluating
adherence initiatives with all of its vendors. This will mainly
impact our fourth quarter results and, therefore, we are trimming
our guidance ranges to reflect this cancellation. I do not see this
as a negative reflection on our core business, but rather an
external event that will have a minor short-term impact for the
remainder of 2019.”
Financial Performance for the Three Months Ended
September 30, 2019
All comparisons, unless otherwise noted, are to the three months
ended September 30, 2018.
- Total revenue was $74.3 million, an increase of 36%. Total
revenue included product revenue of $35.0 million, an increase of
25%, largely driven by expansion from existing clients and the
onboarding of new clients since the end of the third quarter of
2018. Service revenue was $39.3 million, an increase of 49% that
was driven by expanded services offered to existing clients as well
as a contribution from recent acquisitions. Software related
revenue represented 18% of total revenue as compared to 4% for the
three months ended September 30, 2018.
- Gross margin, excluding depreciation and amortization expense,
a non-GAAP measure, was 37.5% compared to 35.6%. The year-over-year
increase resulted from continued growth in services, which was
approximately 53% of total revenue as compared to 48% last year. As
previously announced during the first quarter of 2019, TRHC
increased its long-term gross margin target range, excluding
depreciation and amortization, to 40% to 45%. This increase
resulted from an acceleration of TRHC’s plans to diversify its
revenue base with more services due to the acquisition of
PrescribeWellness.
- Non-GAAP Adjusted EBITDA was $10.6 million compared to $9.3
million, an increase of 14%. The increase in Non-GAAP Adjusted
EBITDA was due to organic and inorganic growth in the PACE, health
plan and pharmacy markets.
- Non-GAAP Adjusted EBITDA margin decreased from 17.0% to 14.2%
based on an adherence contract termination during the quarter,
remaining in line with management’s expectations. TRHC believes
full year Adjusted EBITDA margins will end about 2% lower than 2018
due to investments in DoseMe, which was acquired in January 2019,
the Precision Pharmacotherapy Research and Development Institute in
Lake Nona Medical City as well as TRHC’s sales infrastructure in
order to support future growth.
- Net loss was $8.1 million compared to net income of $10.4
million. The primary factors contributing to the net loss were
stock-based compensation expense of $7.2 million, depreciation and
amortization of $9.1 million, interest expense of $4.4 million and
changes in the fair values of acquisition-related contingent
consideration of $1.5 million relating to the acquisitions of
Cognify and DoseMe. Net income in the third quarter of 2018 was
significantly impacted by a benefit of $8.3 million due to the
change in fair value of acquisition-related contingent
consideration for the SRx acquisition.
- Net loss per diluted share was $0.39, compared to net income
per diluted share of $0.47. The net loss per share calculations
were based on a diluted share count of 20.7 million for the third
quarter of 2019, compared to 22.3 million shares for the same
period in 2018.
- Non-GAAP Adjusted net income per diluted share, or Adjusted
Diluted EPS, was $0.22, a decrease compared to $0.26 in the third
quarter of 2018. The net income per share calculations were based
on a diluted share count of 23.1 million for the third quarter of
2019, compared to 22.3 million for the same period in
2018.
- Unrestricted cash at the end of the third quarter was $47.3
million compared to $20.3 million at December 31, 2018. No amounts
were drawn on TRHC’s $60 million line of credit.
A reconciliation of generally accepted accounting principles
(“GAAP”) in the United States to non-GAAP results has been provided
in this press release in the accompanying tables. An explanation of
these measures is also included below under the heading “Non-GAAP
Financial Measures.”
Financial Outlook
Fourth Quarter 2019 Guidance: Revenue for
TRHC’s fourth quarter in 2019 is expected to be in the range of
$71.0 million to $74.0 million. Net loss is expected to be in the
range of $11.9 million to $11.1 million. Adjusted EBITDA is
expected to be in the range of $6.0 million to $7.0 million.
Full Year 2019 Guidance: Revenue for fiscal
year 2019 is now expected to be in the range of $282.0 million to
$285.0 million. TRHC expects a net loss in the range of $37.7
million to $36.8 million. These net loss projections do not include
any future adjustments to contingent consideration liabilities for
the Cognify acquisition. Adjusted EBITDA is expected to be in the
range of $35.9 million to $36.9 million.
Quarterly Conference Call
As previously announced, TRHC will hold a conference call with
members of executive management to discuss its third quarter 2019
performance today, Thursday, November 7, 2019, at 5:00 p.m. ET.
Stockholders and interested participants may listen to a live
broadcast of the conference call by dialing 844-413-0947 or
216-562-0423 for international callers, and referencing participant
code 9977524 approximately 15 minutes prior to the call. A live
webcast of the conference call will be available on the investor
relations section of TRHC’s website (ir.trhc.com) and an audio file
of the call will also be archived and available for replay
approximately two hours after the live event for a period of 90
days thereafter at ir.trhc.com. After the conference call, a replay
will be available until November 14, 2019 and can be accessed by
dialing 855-859-2056 or 404-537-3406 for international callers, and
referencing participant code 9977524.
About Tabula Rasa HealthCare
TRHC (NASDAQ:TRHC) is a leader in providing patient-specific,
data-driven technology and solutions that enable healthcare
organizations to optimize medication regimens to improve patient
outcomes, reduce hospitalizations, lower healthcare costs, and
manage risk. TRHC provides solutions for a range of payers,
providers, and other healthcare organizations. For more
information, visit: www.trhc.com.
Non-GAAP Financial Measures
In addition to reporting all financial information required in
accordance with GAAP, TRHC is also reporting gross margin excluding
depreciation and amortization expense, Adjusted EBITDA and Adjusted
Diluted EPS, each of which is considered a non-GAAP financial
measure. Generally, a non-GAAP financial measure is a numerical
measure of a company's performance or financial position that
either excludes or includes amounts that are not normally excluded
or included in the most directly comparable measure calculated and
presented in accordance with GAAP.
Adjusted EBITDA consists of net income or loss excluding certain
other expenses, which includes interest expense, provision
(benefit) for income tax, depreciation and amortization, change in
fair value of acquisition-related contingent consideration expense,
acquisition-related expense, stock-based compensation expense and
severance expense. TRHC defines Adjusted Diluted EPS as net income
or loss attributable to common stockholders before fair value
adjustments for acquisition-related contingent consideration,
amortization of acquired intangibles, amortization of debt discount
and issuance costs, acquisition-related expense, stock-based
compensation expense, severance expense and the tax impact of using
a normalized tax rate on pre-tax income adjusted for those items
expressed on a per share basis using weighted average diluted
shares outstanding. TRHC considers acquisition-related expense to
include non-recurring direct transaction and integration costs,
severance, and the impact of purchase accounting adjustments
related to the fair value of acquired deferred revenue. TRHC
believes the exclusion of these items assists in providing a more
complete understanding of the company’s underlying operations
results and trends and allows for comparability with TRHC’s peer
company index and industry and to be more consistent with TRHC’s
expected capital structure on a going forward basis. Please note
that other companies might define their non-GAAP financial measures
differently than TRHC does.
TRHC presents these non-GAAP financial measures in this release
because it considers them to be important supplemental measures of
performance. TRHC uses these non-GAAP financial measures for
planning purposes, including analysis of the company's performance
against prior periods, the preparation of operating budgets and
determination of appropriate levels of operating and capital
investments. TRHC believes that these non-GAAP financial measures
provide additional insight for analysts and investors in evaluating
the company's financial and operational performance. TRHC also
intends to provide these non-GAAP financial measures as part of the
company's future earnings discussions and, therefore, their
inclusion should provide consistency in the company's financial
reporting.
Non-GAAP financial measures have limitations as an analytical
tool. Investors are encouraged to review the reconciliation of
Adjusted EBITDA and Adjusted Diluted EPS to their most directly
comparable GAAP measures provided in this release, including in the
accompanying tables.
Safe Harbor Statement
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of
1934, as amended, that we believe to be reasonable as of today’s
date. Forward-looking statements give current expectation or
forecasts of future events or our future financial or operating
performance, and include TRHC’s expectations regarding healthcare
regulations, industry trends, available opportunities to TRHC and
the financial and operating performance of TRHC, including with
respect to international expansion and integration of recent
acquisitions. Such statements are identified by use of the words
“anticipates,” “believes,” “estimates,” “expects,” “intends,”
“plans,” “predicts,” “projects,” “should,” and similar
expressions. These forward-looking statements are based on
management's good-faith expectations, judgements and assumptions as
of the date of this press release. Actual results might
differ materially from those explicit or implicit in the
forward-looking statements. Important factors that could cause
actual results to differ materially include: our continuing losses
and need to achieve profitability; fluctuations in our financial
results; the acceptance and use of our products and services by
PACE organizations; the need to innovate and provide useful
products and services; risks related to changing healthcare and
other applicable regulations; our ability to maintain relationships
with a specified drug wholesaler; increasing consolidation in the
healthcare industry; managing our growth effectively; our ability
to adequately protect our intellectual property; the requirements
of being a public company; our ability to recognize the expected
benefits from acquisitions on a timely basis or at all; and the
other risk factors set forth from time to time in our filings with
the Securities and Exchange Commission (“SEC”), including
those factors discussed under the caption “Risk Factors” in our
most recent annual report on Form 10-K, filed with the SEC on March
1, 2019, and in subsequent reports filed with or furnished to the
SEC, copies of which are available free of charge within the
Investor Relations section of the Tabula Rasa HealthCare website
http://ir.trhc.com or upon request from our Investor Relations
Department. Tabula Rasa HealthCare assumes no obligation and does
not intend to update these forward-looking statements, except as
required by law, to reflect events or circumstances occurring after
today’s date.
TABULA RASA
HEALTHCARE, INC.UNAUDITED CONSOLIDATED
BALANCE SHEETS(In thousands)
|
|
|
|
|
|
|
|
|
September 30, |
|
December 31, |
|
|
2019 |
|
|
2018 |
|
Assets |
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash |
|
$ |
47,302 |
|
|
$ |
20,278 |
|
Restricted cash |
|
|
3,767 |
|
|
|
4,751 |
|
Accounts receivable, net |
|
|
30,984 |
|
|
|
27,950 |
|
Inventories |
|
|
3,814 |
|
|
|
3,594 |
|
Prepaid expenses |
|
|
3,175 |
|
|
|
2,573 |
|
Other current assets |
|
|
7,643 |
|
|
|
4,165 |
|
Total current assets |
|
|
96,685 |
|
|
|
63,311 |
|
Property and equipment,
net |
|
|
15,537 |
|
|
|
11,865 |
|
Operating lease right-of-use
assets |
|
|
22,140 |
|
|
|
— |
|
Software development costs,
net |
|
|
15,830 |
|
|
|
8,248 |
|
Goodwill |
|
|
150,790 |
|
|
|
108,213 |
|
Intangible assets, net |
|
|
196,419 |
|
|
|
77,206 |
|
Deferred income tax
assets |
|
|
— |
|
|
|
75 |
|
Note receivable |
|
|
— |
|
|
|
1,000 |
|
Other assets |
|
|
1,332 |
|
|
|
1,039 |
|
Total assets |
|
$ |
498,733 |
|
|
$ |
270,957 |
|
Liabilities and
stockholders’ equity |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Current portion of long-term debt and finance leases, net |
|
$ |
334 |
|
|
$ |
945 |
|
Current operating lease liabilities |
|
|
4,214 |
|
|
|
— |
|
Acquisition-related contingent consideration |
|
|
— |
|
|
|
43,397 |
|
Accounts payable |
|
|
11,001 |
|
|
|
14,830 |
|
Accrued expenses and other liabilities |
|
|
28,015 |
|
|
|
16,556 |
|
Total current liabilities |
|
|
43,564 |
|
|
|
75,728 |
|
Line of credit |
|
|
— |
|
|
|
45,000 |
|
Long-term debt and finance
leases, net |
|
|
223,208 |
|
|
|
152 |
|
Noncurrent operating lease
liabilities |
|
|
21,231 |
|
|
|
— |
|
Long-term acquisition-related
contingent consideration |
|
|
11,500 |
|
|
|
7,800 |
|
Deferred income tax
liability |
|
|
14,371 |
|
|
|
— |
|
Other long-term
liabilities |
|
|
93 |
|
|
|
3,268 |
|
Total liabilities |
|
|
313,967 |
|
|
|
131,948 |
|
|
|
|
|
|
|
|
Stockholders' equity: |
|
|
|
|
|
|
Common stock |
|
|
2 |
|
|
|
2 |
|
Additional paid-in capital |
|
|
280,739 |
|
|
|
209,330 |
|
Treasury stock |
|
|
(3,865 |
) |
|
|
(3,825 |
) |
Accumulated deficit |
|
|
(92,110 |
) |
|
|
(66,498 |
) |
Total stockholders’
equity |
|
|
184,766 |
|
|
|
139,009 |
|
Total liabilities and
stockholders’ equity |
|
$ |
498,733 |
|
|
$ |
270,957 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TABULA RASA
HEALTHCARE, INC.UNAUDITED CONSOLIDATED
STATEMENTS OF OPERATIONS(In thousands, except
share and per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
|
September 30, |
|
September 30, |
|
|
2019 |
|
|
2018 |
|
|
2019 |
|
|
2018 |
|
Revenue: |
|
|
|
|
|
|
|
|
|
Product revenue |
|
$ |
34,966 |
|
|
$ |
28,045 |
|
|
$ |
99,320 |
|
|
$ |
82,603 |
|
Service revenue |
|
|
39,304 |
|
|
|
26,373 |
|
|
|
112,164 |
|
|
|
64,357 |
|
Total revenue |
|
|
74,270 |
|
|
|
54,418 |
|
|
|
211,484 |
|
|
|
146,960 |
|
Cost of revenue, exclusive of
depreciation and amortization shown below: |
|
|
|
|
|
|
|
|
|
|
|
|
Product cost |
|
|
25,931 |
|
|
|
21,100 |
|
|
|
74,267 |
|
|
|
62,007 |
|
Service cost |
|
|
20,510 |
|
|
|
13,958 |
|
|
|
58,998 |
|
|
|
37,125 |
|
Total cost of revenue, exclusive of depreciation and
amortization |
|
|
46,441 |
|
|
|
35,058 |
|
|
|
133,265 |
|
|
|
99,132 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
5,902 |
|
|
|
3,380 |
|
|
|
16,649 |
|
|
|
8,515 |
|
Sales and marketing |
|
|
6,884 |
|
|
|
2,669 |
|
|
|
18,605 |
|
|
|
6,985 |
|
General and administrative |
|
|
12,155 |
|
|
|
7,824 |
|
|
|
38,781 |
|
|
|
20,229 |
|
Change in fair value of acquisition-related contingent
consideration expense (income) |
|
|
1,510 |
|
|
|
(8,419 |
) |
|
|
4,516 |
|
|
|
40,385 |
|
Depreciation and amortization |
|
|
9,142 |
|
|
|
4,096 |
|
|
|
24,519 |
|
|
|
12,110 |
|
Total operating
expenses |
|
|
35,593 |
|
|
|
9,550 |
|
|
|
103,070 |
|
|
|
88,224 |
|
(Loss) income from
operations |
|
|
(7,764 |
) |
|
|
9,810 |
|
|
|
(24,851 |
) |
|
|
(40,396 |
) |
Interest expense, net |
|
|
4,441 |
|
|
|
232 |
|
|
|
11,442 |
|
|
|
415 |
|
(Loss) income before income
taxes |
|
|
(12,205 |
) |
|
|
9,578 |
|
|
|
(36,293 |
) |
|
|
(40,811 |
) |
Income tax benefit |
|
|
(4,101 |
) |
|
|
(838 |
) |
|
|
(10,681 |
) |
|
|
(4,107 |
) |
Net (loss) income |
|
$ |
(8,104 |
) |
|
$ |
10,416 |
|
|
$ |
(25,612 |
) |
|
$ |
(36,704 |
) |
Net (loss) income per
share: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
(0.39 |
) |
|
$ |
0.54 |
|
|
$ |
(1.25 |
) |
|
$ |
(1.93 |
) |
Diluted |
|
$ |
(0.39 |
) |
|
$ |
0.47 |
|
|
$ |
(1.25 |
) |
|
$ |
(1.93 |
) |
Weighted average common shares
outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
20,691,112 |
|
|
|
19,217,623 |
|
|
|
20,520,357 |
|
|
|
18,989,334 |
|
Diluted |
|
|
20,691,112 |
|
|
|
22,288,873 |
|
|
|
20,520,357 |
|
|
|
18,989,334 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TABULA RASA
HEALTHCARE, INC.UNAUDITED CONSOLIDATED
STATEMENTS OF CASH FLOWS(In
thousands)
|
|
|
|
|
|
|
|
|
Nine Months Ended |
|
|
September 30, |
|
|
2019 |
|
|
2018 |
|
Cash flows from
operating activities: |
|
|
|
|
|
Net loss |
|
$ |
(25,612 |
) |
|
$ |
(36,704 |
) |
Adjustments to reconcile net
loss to net cash (used in) provided by operating activities: |
|
|
|
|
|
|
Depreciation and amortization |
|
|
24,519 |
|
|
|
12,110 |
|
Amortization of deferred financing costs and debt discount |
|
|
7,689 |
|
|
|
66 |
|
Deferred taxes |
|
|
(10,749 |
) |
|
|
(4,536 |
) |
Stock-based compensation |
|
|
20,983 |
|
|
|
7,121 |
|
Change in fair value of acquisition-related contingent
consideration |
|
|
4,516 |
|
|
|
40,385 |
|
Acquisition-related contingent consideration paid |
|
|
(24,480 |
) |
|
|
— |
|
Other noncash items |
|
|
12 |
|
|
|
51 |
|
Changes in operating assets and liabilities, net of effect from
acquisitions: |
|
|
|
|
|
|
Accounts receivable, net |
|
|
(417 |
) |
|
|
(7,035 |
) |
Inventories |
|
|
(220 |
) |
|
|
(818 |
) |
Prepaid expenses and other current assets |
|
|
(2,626 |
) |
|
|
(4,915 |
) |
Other assets |
|
|
(53 |
) |
|
|
267 |
|
Accounts payable |
|
|
(5,787 |
) |
|
|
(5,163 |
) |
Accrued expenses and other liabilities |
|
|
5,474 |
|
|
|
8,421 |
|
Other long-term liabilities |
|
|
(60 |
) |
|
|
(7 |
) |
Net cash (used in) provided by
operating activities |
|
|
(6,811 |
) |
|
|
9,243 |
|
|
|
|
|
|
|
|
Cash flows from
investing activities: |
|
|
|
|
|
|
Purchases of property and
equipment |
|
|
(5,202 |
) |
|
|
(3,484 |
) |
Software development
costs |
|
|
(10,285 |
) |
|
|
(3,564 |
) |
Purchases of intangible
assets |
|
|
(1,202 |
) |
|
|
(29 |
) |
Proceeds from repayment of
note receivable |
|
|
1,000 |
|
|
|
— |
|
Acquisitions of businesses,
net of cash acquired |
|
|
(158,762 |
) |
|
|
(21,981 |
) |
Net cash used in investing
activities |
|
|
(174,451 |
) |
|
|
(29,058 |
) |
|
|
|
|
|
|
|
Cash flows from
financing activities: |
|
|
|
|
|
|
Payments for repurchase of
common stock |
|
|
— |
|
|
|
(2,866 |
) |
Proceeds from exercise of
stock options |
|
|
2,503 |
|
|
|
2,590 |
|
Payments for debt financing
costs |
|
|
(9,632 |
) |
|
|
(103 |
) |
Borrowings on line of
credit |
|
|
— |
|
|
|
26,500 |
|
Repayments of line of
credit |
|
|
(45,000 |
) |
|
|
— |
|
Payments of equity offering
costs |
|
|
— |
|
|
|
(364 |
) |
Payments of
acquisition-related contingent consideration |
|
|
(29,062 |
) |
|
|
(1,646 |
) |
Repayments of long-term debt
and finance leases |
|
|
(757 |
) |
|
|
(779 |
) |
Proceeds from issuance of
convertible senior subordinated notes |
|
|
325,000 |
|
|
|
— |
|
Proceeds from sale of
warrants |
|
|
65,910 |
|
|
|
— |
|
Purchase of convertible note
hedges |
|
|
(101,660 |
) |
|
|
— |
|
Net cash provided by financing
activities |
|
|
207,302 |
|
|
|
23,332 |
|
Net increase in cash and
restricted cash |
|
|
26,040 |
|
|
|
3,517 |
|
Cash and restricted cash,
beginning of period |
|
|
25,029 |
|
|
|
10,430 |
|
Cash and restricted cash, end
of period |
|
$ |
51,069 |
|
|
$ |
13,947 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TABULA RASA
HEALTHCARE, INC.UNAUDITED RECONCILIATION OF
GAAP TO NON-GAAP MEASURES(In thousands except
share and per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
|
2019 |
|
|
2018 |
|
|
2019 |
|
|
2018 |
|
Reconciliation of net
(loss) income to Adjusted EBITDA |
|
|
|
|
|
|
|
|
|
Net (loss) income |
|
$ |
(8,104 |
) |
|
$ |
10,416 |
|
|
$ |
(25,612 |
) |
|
$ |
(36,704 |
) |
Add: |
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense, net |
|
|
4,441 |
|
|
|
232 |
|
|
|
11,442 |
|
|
|
415 |
|
Income tax benefit |
|
|
(4,101 |
) |
|
|
(838 |
) |
|
|
(10,681 |
) |
|
|
(4,107 |
) |
Depreciation and amortization |
|
|
9,142 |
|
|
|
4,096 |
|
|
|
24,519 |
|
|
|
12,110 |
|
Change in fair value of acquisition-related contingent
consideration expense (income) |
|
|
1,510 |
|
|
|
(8,419 |
) |
|
|
4,516 |
|
|
|
40,385 |
|
Severance expense |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
390 |
|
Acquisition-related expense |
|
|
463 |
|
|
|
783 |
|
|
|
4,752 |
|
|
|
1,123 |
|
Payroll tax expense related to stock option exercises |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
99 |
|
Stock-based compensation expense |
|
|
7,225 |
|
|
|
2,996 |
|
|
|
20,983 |
|
|
|
7,121 |
|
Adjusted EBITDA |
|
$ |
10,576 |
|
|
$ |
9,266 |
|
|
$ |
29,919 |
|
|
$ |
20,832 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
|
|
2019 |
|
|
2018 |
|
2019 |
|
|
2018 |
|
|
Reconciliation of
diluted net (loss) income per share to Adjusted Diluted
EPS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP net (loss) income, basic, and net (loss) income per share,
basic |
|
$ |
(8,104 |
) |
|
$ |
(0.39 |
) |
|
$ |
10,416 |
|
|
$ |
0.54 |
|
$ |
(25,612 |
) |
|
$ |
(1.25 |
) |
|
$ |
(36,704 |
) |
|
$ |
(1.93 |
) |
|
GAAP net (loss) income,
diluted, and net (loss) income per share, diluted |
|
$ |
(8,104 |
) |
|
$ |
(0.39 |
) |
|
$ |
10,416 |
|
|
$ |
0.47 |
|
$ |
(25,612 |
) |
|
$ |
(1.25 |
) |
|
$ |
(36,704 |
) |
|
$ |
(1.93 |
) |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in fair value of acquisition-related contingent
consideration expense (income) |
|
|
1,510 |
|
|
|
|
|
|
(8,419 |
) |
|
|
|
|
|
4,516 |
|
|
|
|
|
|
40,385 |
|
|
|
|
|
Amortization of acquired intangibles |
|
|
6,927 |
|
|
|
|
|
|
2,782 |
|
|
|
|
|
|
18,678 |
|
|
|
|
|
|
7,949 |
|
|
|
|
|
Amortization of debt discount and issuance costs |
|
|
3,012 |
|
|
|
|
|
|
— |
|
|
|
|
|
|
7,506 |
|
|
|
|
|
|
— |
|
|
|
|
|
Acquisition-related expense |
|
|
463 |
|
|
|
|
|
|
783 |
|
|
|
|
|
|
4,752 |
|
|
|
|
|
|
1,123 |
|
|
|
|
|
Payroll tax expense on stock option exercises |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
99 |
|
|
|
|
|
Stock-based compensation expense |
|
|
7,225 |
|
|
|
|
|
|
2,996 |
|
|
|
|
|
|
20,983 |
|
|
|
|
|
|
7,121 |
|
|
|
|
|
Severance expense |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
390 |
|
|
|
|
|
Impact to income taxes (1) |
|
|
(6,049 |
) |
|
|
|
|
|
(2,718 |
) |
|
|
|
|
|
(15,716 |
) |
|
|
|
|
|
(8,123 |
) |
|
|
|
|
Adjusted net income and Adjusted Diluted EPS |
|
$ |
4,984 |
|
|
$ |
0.22 |
|
|
$ |
5,840 |
|
|
$ |
0.26 |
|
$ |
15,107 |
|
|
$ |
0.66 |
|
|
$ |
12,240 |
|
|
$ |
0.56 |
|
|
(1) The impact to taxes was calculated using a normalized
statutory tax rate applied to pre-tax (loss) income adjusted for
the respective items above and then subtracting the tax provision
as determined for GAAP purposes.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
|
September 30, |
|
September 30, |
|
|
2019 |
|
2018 |
|
2019 |
|
2018 |
Reconciliation of
weighted average shares of common stock outstanding, diluted, to
weighted average shares of common stock outstanding, diluted for
Adjusted Diluted EPS |
|
|
|
|
|
|
|
|
Weighted average shares of
common stock outstanding, basic for GAAP |
|
20,691,112 |
|
19,217,623 |
|
20,520,357 |
|
18,989,334 |
Effect of potential dilutive securities: |
|
|
|
|
|
|
|
|
Weighted average dilutive effect of stock options |
|
— |
|
1,898,543 |
|
— |
|
— |
Weighted average dilutive effect of restricted shares |
|
— |
|
898,821 |
|
— |
|
— |
Weighted average dilutive effect of contingent shares |
|
— |
|
273,886 |
|
— |
|
— |
Weighted average shares of common stock outstanding, diluted for
GAAP |
|
20,691,112 |
|
22,288,873 |
|
20,520,357 |
|
18,989,334 |
Adjustments: |
|
|
|
|
|
|
|
|
Weighted average dilutive effect of stock options |
|
1,555,922 |
|
— |
|
1,577,258 |
|
1,710,175 |
Weighted average dilutive effect of restricted stock |
|
809,601 |
|
— |
|
803,618 |
|
846,802 |
Weighted average dilutive effect of contingent shares |
|
30,502 |
|
— |
|
27,037 |
|
142,679 |
Weighted average shares of common stock outstanding, diluted for
Adjusted Diluted EPS (1) |
|
23,087,137 |
|
22,288,873 |
|
22,928,270 |
|
21,688,990 |
(1) TRHC accounts for the convertible senior subordinated notes
utilizing the Treasury Stock Method as it intends to settle the
notes entirely or partly in cash. Under this method, the underlying
shares of TRHC common stock issuable upon conversion of the notes
are excluded from the calculation of diluted EPS, except to the
extent that the average stock price for the reporting period
exceeds their conversion price of $69.95 per share. For the three
and nine months ended September 30, 2019, there was no impact on
diluted EPS from the convertible senior subordinated notes as the
conversion price exceeded TRHC’s average stock price.
TABULA RASA
HEALTHCARE, INC.UNAUDITED RECONCILIATION OF
GAAP TO NON-GAAP GUIDANCE RANGES(In
millions)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LOW |
|
HIGH |
|
LOW |
|
HIGH |
|
|
Three Months Ended December 31, 2019 |
|
Year Ended December 31, 2019 |
Reconciliation from
Net Loss Guidance to Adjusted EBITDA Guidance |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss: |
|
$ |
(11.9 |
) |
|
$ |
(11.1 |
) |
|
$ |
(37.7 |
) |
|
$ |
(36.8 |
) |
Add: |
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
4.5 |
|
|
|
4.5 |
|
|
|
16.0 |
|
|
|
16.0 |
|
Income tax benefit |
|
|
(2.4 |
) |
|
|
(2.2 |
) |
|
|
(13.0 |
) |
|
|
(12.9 |
) |
Depreciation and amortization |
|
|
9.2 |
|
|
|
9.2 |
|
|
|
33.7 |
|
|
|
33.7 |
|
Stock-based compensation expense |
|
|
6.6 |
|
|
|
6.6 |
|
|
|
27.6 |
|
|
|
27.6 |
|
Change in fair value of contingent consideration |
|
|
— |
|
|
|
— |
|
|
|
4.5 |
|
|
|
4.5 |
|
Acquisition-related expense |
|
|
— |
|
|
|
— |
|
|
|
4.8 |
|
|
|
4.8 |
|
Adjusted EBITDA |
|
$ |
6.0 |
|
|
$ |
7.0 |
|
|
$ |
35.9 |
|
|
$ |
36.9 |
|
Contact:
InvestorsBob East or Asher DewhurstWestwicke
Partners443-213-0500tabularasa@westwicke.com
MediaDianne Semingsondsemingson@TRHC.comT: 215-870-0829
Tabula Rasa HealthCare (NASDAQ:TRHC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tabula Rasa HealthCare (NASDAQ:TRHC)
Historical Stock Chart
From Apr 2023 to Apr 2024